Recent Updates
Recently added Catalysts

Acute Lymphoblastic Leukemia: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$203Muniverse median $1.20B
Allocated capital$13M$203M competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank297/299crowding rank 297

Acute Lymphoblastic Leukemia is uncontested. Precision BioSciences (DTIL) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with pCAR-19B cells in phase 2.

There is no public comparable to price it against. DTIL spreads its $203M market cap across 16 indications, so $13M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$13M of allocated capital sits in Acute Lymphoblastic Leukemia, ranking it 297th of 299 indications by the money committed to it.

Companies developing drugs for Acute Lymphoblastic Leukemia 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
DTILPrecision BioSciencespCAR-19B cellsPhase 21$203MNo16 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Acute Lymphoblastic Leukemia counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Acute Lymphoblastic Leukemia has one competitor and a median of $203M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Relapsed or Refractory Multiple Myeloma1 company · $13M · median $203MUncontestedRelapsed or Refractory Acute Lymphoblastic Leukemia1 company · $13M · median $203MUncontestedAggressive B-Cell Non-Hodgkin's Lymphoma1 company · $34M · median $168MUncontestedFollicular Lymphoma1 company · $34M · median $168MUncontestedPediatric Brain Tumor1 company · $41M · median $124MUncontestedMetastatic Anal Cancer1 company · $51M · median $102MUncontestedMetastatic Pancreatic Adenocarcinoma1 company · $53M · median $371MUncontestedNewly Diagnosed Glioblastoma1 company · $53M · median $371MUncontested

Acute Lymphoblastic Leukemia pipeline questions

Which biotech companies are developing drugs for Acute Lymphoblastic Leukemia?

Precision BioSciences (DTIL, pCAR-19B cells, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Acute Lymphoblastic Leukemia.

How advanced is the Acute Lymphoblastic Leukemia pipeline?

Of the 1 clinical-stage programme in Acute Lymphoblastic Leukemia, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Acute Lymphoblastic Leukemia?

No. DTIL is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Acute Lymphoblastic Leukemia, which is why the indication is classified as uncontested.

When is the next Acute Lymphoblastic Leukemia catalyst?

The next dated catalyst in Acute Lymphoblastic Leukemia is DTIL on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map